Bio-Rad Laboratories, Inc.
BIO
$242.40
-$10.76-4.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -571.33% | -189.38% | -388.82% | -209.46% | -68.58% |
| Total Depreciation and Amortization | 3.53% | 3.91% | 3.74% | 4.82% | 5.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 267.19% | 113.12% | 118.26% | 111.45% | 11.80% |
| Change in Net Operating Assets | -86.47% | -43.44% | -48.78% | -42.17% | 28.81% |
| Cash from Operations | 48.68% | 21.42% | 10.31% | 20.69% | 43.20% |
| Capital Expenditure | 0.84% | -5.69% | -10.55% | -27.18% | -39.63% |
| Sale of Property, Plant, and Equipment | -63.00% | -63.00% | 45.03% | 146.74% | 24.22% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 83.82% |
| Other Investing Activities | -77.90% | -96.93% | 171.89% | 252.29% | 239.91% |
| Cash from Investing | -340.07% | -893.10% | 48.01% | 94.02% | 113.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 34.70% | 3.60% | -20.33% | -20.53% | -12.28% |
| Issuance of Common Stock | -8.08% | 3.76% | 5.98% | 2.82% | 9.93% |
| Repurchase of Common Stock | 32.15% | 53.35% | -24.86% | -9.56% | -95.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,897.17% | -- | -1,150.00% | -1,150.00% | -1,150.00% |
| Cash from Financing | 26.37% | 48.59% | -26.15% | -10.19% | -102.40% |
| Foreign Exchange rate Adjustments | -7.04% | 2,209.25% | 33.82% | 162.52% | 186.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 20.93% | -100.00% | -100.00% |
| Net Change in Cash | 391.32% | 383.78% | 23.18% | 108.39% | 90.93% |